Navigation Links
Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
Date:4/20/2009

EMERYVILLE, Calif., April 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the poster presentation of significant, new data on the nature of the active compound and mechanism of action for its preclinical cancer drug candidate, BN108. The presentation is being made at the 2009 conference of the American Association of Cancer Research (AACR) in Denver, today.

In summary, the study concludes the following:

  • BN108, an aqueous extract of Anemarrhena asphodeloides, selectively induces cell death in breast cancer cells and other tumor cells without having a toxic effect on normal cells.
  • Timosaponin AIII (TAIII) has been identified as an active compound from BN108 that is responsible for the selective activity of BN108 towards breast cancer cells.
  • BN108 and TAIII rapidly and selectively inhibited major pro-survival cellular pathways that are often over-active in breast cancer.

"Currently available treatments for advanced breast cancer patients have limited efficacy and are associated with severe toxicity. Significantly more effective, less toxic therapies are urgently needed. Our studies suggest that therapeutic strategies based on BN108 and TspA3 may achieve more efficacious and safer clinical outcomes for breast cancer patients," stated Emma Shtivelman, Ph.D., the director of cancer research at Bionovo.

"BN108 offers great potential for the treatment of cancer. It is a drug that targets cell survival mechanisms, but it does it only in cancer cells. We anticipate it will have little to no collateral toxicity as is observed with all current cancer chemotherapy," said Isaac Cohen, chairman and CEO of Bionovo, Inc. "Bionovo is looking forward to entering clinical testing with BN108. We be
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bionovo Announces 2008 Highlights and Year-End Financial Results
2. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
3. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
4. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
5. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
6. Bionovo to Present at the Piper Jaffray Healthcare Conference
7. Ethan Weiss, M.D., Joins Bionovos Scientific Advisory Board
8. Bionovo Reports Third Quarter 2008 Financial Results
9. Bionovo to Present at Merriman Curhan Fords Investor Summit 2008 on September 15th
10. Bionovo to Present at Canaccord Adams Global Growth Conference
11. Bionovo Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... PRINCETON, N.J. , Sept. 17, 2014 /PRNewswire/ ... developing targeted therapeutic devices to address infectious disease, cancer ... Sciences, Inc. (ESI), disclosed today that each company will ... Summit. On September 18 th , ... presentation entitled: "Exosomes: A Multiplexed Platform for Clinical Management." ...
(Date:9/17/2014)... JH Technologies announces the grand opening ... JH Technologies, a leader in sales and support of ... partnership with Leica Microsystems into the Southern California market. ... will be featured at the grand opening slated for ... is located within the JH Technologies office’s at 18025 ...
(Date:9/17/2014)... 2014 Intarcia Therapeutics, Inc. today ... study of the cost and predictability of non-adherence in ... Annual Meeting of the European Association for the Study ... Christian Frois , Ph.D., of Analysis Group, Inc. presented ... Intarcia-sponsored, retrospective studies to characterize the prevalence of non-adherence ...
Breaking Biology Technology:Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... to Accelerate Workflow, CHICAGO, Nov. 27 ... the MAMMOMAT(R) Novation S, a new,digital mammography ... at the 93rd Scientific Assembly and Annual ... (RSNA) from Nov. 25 to 30 at,McCormick ...
... of Health, Labor and Welfare (MHLW), for the revolutionary ... ... the blood, IRVINE, Calif., Nov. 27 Masimo, the ... today announced approval of the Masimo Rad-57 Pulse CO-Oximeter,bringing the ...
... UCLA,s California NanoSystems Institute, the David Geffen School of ... have modeled the structure of the largest cellular particle ... drug delivery. , The research study, ... as a drug-therapy vehicle, appears in the Nov. 27 ...
Cached Biology Technology:Siemens Unveils New Digital Mammography System for Optimized Screening 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 2Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 3Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan 4Researchers outline structure of largest nonvirus particle ever crystallized 2
(Date:9/17/2014)... a new crime unit designed to fight food fraud ... horse meat being passed off as beef scientists ... adulteration. They describe their approach, which represents a vast ... Agricultural and Food Chemistry . , Hans-Ulrich Humpf and ... economic problem. But they also say that adding, for ...
(Date:9/16/2014)... for Children,s Environmental Health at the Mailman School of ... between childhood asthma and prenatal exposure to two phthalates ... appear online in the journal Environmental Health Perspectives ... pregnancy to higher levels of the chemicals, butylbenzyl phthalate ... and 78 percent increase in risk of developing asthma ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5
... Wireless ... for Emergency Responders, WALL, N.J., Oct. 15 BIO-key ... and wireless public safety solutions, today announced that,it will be ... Chiefs of Police (IACP) Conference and,Exposition, October 15-17 at the ...
... (AD) is a progressive neurodegenerative disorder characterized by ... amyloid plaques and neurofibrillary tangles. Neuronal and synaptic ... occur in specific brain areas involved in memory ... cerebral deposition of A" plays a seminal role ...
... to ramp up testosterone production appears to drive male ... comes with an evolutionary cost. Big fluctuations in testosterone ... their own young, scientists have learned. In ... Indiana University Bloomington, University of Virginia and University of ...
Cached Biology News:BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 2BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference 3Paradigm shift in Alzheimers's research: new treatments 2Paradigm shift in Alzheimers's research: new treatments 3Paradigm shift in Alzheimers's research: new treatments 4Testosterone turns male juncos into blustery hunks -- and bad dads 2Testosterone turns male juncos into blustery hunks -- and bad dads 3
Peptide-affinity Purified Polyclonal Antibody to Purinergic Receptor P2Y12...
Purified anti-PXR...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Purified anti-DNA-PKcs Phosphorylated (Thr2609)...
Biology Products: